Future DES Purchasing Strategy: A “Price Is Right” Approach?
This article was originally published in The Gray Sheet
Executive Summary
Pricing strategies and ease of use factors likely will overshadow clinical efficacy as Boston Scientific and Johnson & Johnson joust for dominance in the U.S. drug-eluting stent market
You may also be interested in...
Boston Scientific Taxus Inventory Of 150,000 Planned For U.S. Launch
Boston Scientific projects a 60% U.S. drug-eluting stent market penetration "right out of the gate" for its soon-to-be-launched Taxus, according to Senior VP and Cardiovascular Group President Paul LaViolette
Boston Scientific Taxus Inventory Of 150,000 Planned For U.S. Launch
Boston Scientific projects a 60% U.S. drug-eluting stent market penetration "right out of the gate" for its soon-to-be-launched Taxus, according to Senior VP and Cardiovascular Group President Paul LaViolette
DES Utilization Guidelines Give Guidant Comfort; J&J Revisits Cypher Pricing
Guidant is positioning its Multi-Link bare-metal stent platform to benefit from hospital guidelines limiting drug-eluting stent use to FDA-approved indications